Citation APA
Blumental, S., Lajot, A., Vandromme, M., Lafort, Y., Dockx, Y., Denayer, S., Wampers, A., Nebbioso, A., Tilmanne, A., Mignon, C., Tuerlinckx, D., Rigolle, H., Matthijs, I., Vandersnickt, J., Hellinckx, J., Dewulf, J., Coppens, K., Van Hoorenbeeck, K., Vanlede, K., Winters, L., Seyler, L., Parsy, M.-P., Reynders, M., Balcaen, M., Urbina, M., Dauby, N., Chatzis, O., Naesens, R., Dorval, S., Ternest, S., Vanspeybroeck, S., Goetghebuer, T., Van Ackere, T., Selimaj Kontoni, V., El Bitar, W., Holemans, X., Bruyère, Y., Van Brusselen, D., De Mot, L., & Raes, M. (2026). National real-life impact of prevention with nirsevimab on infants’ RSV hospitalizations in Belgium. BMC infectious diseases. doi:10.1186/s12879-026-13419-y
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/410008